---
title: Lung Cancer Pill Taken for Three Years After Surgery Keeps More Patients Alive at Eight Years
description: Eight-year ADAURA data show osimertinib helps EGFR-mutation lung cancer patients live longer after surgery, if they get tested and finish the three-year course.
author: Dr Marina Nani (Editor-in-Chief)
updated: 2026-09-14T15:16:11.427Z
canonical: https://richhealthmagazine.com/article/osimertinib-lung-cancer-8-year-survival-adaura
categories: Longevity & Science
content_type: News
region: United States
publication: Rich Health Magazine
schema_type: Article
---

Eight years after surgery, 79% of early-stage lung cancer patients who took the targeted pill osimertinib were still alive, compared with 64% of those given a placebo. That finding, from the Phase III ADAURA trial, was presented in September at the IASLC World Conference on Lung Cancer in Seoul and published in the Journal of Thoracic Oncology, with lead author Yi-Long Wu. The osimertinib group had about a 48% lower risk of death (hazard ratio 0.52, 95% CI 0.39 to 0.71). Among patients with more advanced resected disease, stage II to IIIA, 74% were alive at eight years versus 58% on placebo (hazard ratio 0.53).

The benefit is for patients whose tumors carry an EGFR mutation and who had it completely removed by surgery. Osimertinib, sold as Tagrisso, is a once-daily pill that targets that specific mutation. It is taken after the operation to lower the chance the cancer returns, an approach doctors call adjuvant therapy.

## The Gap Held Even After Placebo Patients Switched

The survival gap held even though many placebo patients later switched to osimertinib once their cancer came back, a point the ADAURA investigators call especially notable: the head start from taking the drug straight after surgery was not erased by giving it later. This eight-year figure is what researchers call an exploratory landmark analysis. Overall survival was a secondary measure in the trial, and its main goal was to show the drug delayed the cancer's return, which it did. Earlier results from the same trial, at five years, were published in the New England Journal of Medicine in 2023: 85% of stage II to IIIA patients on osimertinib were alive versus 73% on placebo.

Osimertinib is not a new treatment. The US Food and Drug Administration approved it as adjuvant therapy in December 2020, and national treatment guidelines from the NCCN list it as a preferred option for completely resected stage IB to IIIA EGFR-mutated lung cancer. The difference now is time: the survival advantage is still clearly there most of a decade after surgery.

## You Benefit Only If Your Tumor Is Tested

The drug cannot help a patient whose mutation is never found, and that is where many people miss out. About one in three early-stage lung cancer patients who qualify for EGFR testing under guidelines never receive it, for reasons that have nothing to do with the science: too little tissue from the biopsy, cost, insurance reimbursement, and limited testing capacity at some hospitals.

EGFR mutations are more common than many people assume, and more common in groups that have long been under-tested. They occur in roughly a third of non-small-cell lung cancers overall, in about 44% of tumors in women, and in about 49% of tumors in people who never smoked. Roughly one in five early-stage tumors removed by surgery carries one. If you or a family member is facing lung cancer surgery, asking whether the tumor will be tested for an EGFR mutation is a fair and useful question to put to the care team, because the answer decides whether this treatment is even on the table.

## Finishing the Three Years Matters

The trial gave osimertinib for a fixed three years, but outside the trial most patients do not get that far. A real-world study of US patients on adjuvant osimertinib, presented at the same lung cancer conference, found that only about one-third [complete the full three-year course](https://resources.flatiron.com/publications/real-world-treatment-duration-and-outcomes-among-patients-with-early-stage-nsclc-receiving-adjuvant-osimertinib-a-retrospective-cohort-study), and that stopping early was linked to roughly double the risk of the cancer returning or death. Knowing that finishing is what delivers the benefit can help a patient and their doctor plan around the obstacles that tend to cut treatment short.

Side effects are one of those obstacles, and they are real. In the trial, diarrhea and paronychia, a painful inflammation of the skin around the nails, were common, and about 11% of patients stopped osimertinib because of side effects. Many of these problems can be managed with dose adjustments and supportive care, so telling your oncology team about them early, rather than quietly stopping the pill, gives you the best chance of staying on treatment long enough to get its full protection.

## FAQ

**Q: What is osimertinib (Tagrisso) and how does it work?**
Osimertinib is a once-daily targeted pill for lung cancers driven by a specific EGFR mutation. It blocks the mutated protein that signals those cancer cells to grow. After surgery it is used to lower the chance the cancer comes back.

**Q: Who should be tested for an EGFR mutation after lung cancer surgery?**
Guidelines call for EGFR testing in patients with completely resected non-small-cell lung cancer, because the result determines whether osimertinib can help. Mutations are more common in women and in people who never smoked, but anyone with this type of lung cancer can carry one, so testing should not be skipped based on someone's history.

**Q: How long do you take osimertinib after surgery?**
The ADAURA trial gave it for three years, and that is the intended course. Real-world data show most patients stop earlier, and stopping early is linked to a higher chance of recurrence, so completing the full three years is the goal to discuss with your doctor.

**Q: What are the common side effects of osimertinib?**
Diarrhea and paronychia, a painful inflammation around the nails, were among the most common in the trial. About 11% of patients stopped because of side effects. Many can be eased with dose changes and supportive care, so it is worth raising them with your care team rather than quitting the pill.

**Q: Is adjuvant osimertinib available and approved?**
Yes. The FDA approved it as adjuvant therapy for EGFR-mutated non-small-cell lung cancer in December 2020, and the NCCN lists it as a preferred option for completely resected stage IB to IIIA disease.